Aims: To determine the seroprevalence of Toxoplasma gondii (T. gondii) in women from Aljalla Maternity and Gynaecology Hospital (AMGH) and to evaluate the association between the infection and potential risk factors. Methods: A cross-sectional study was conducted at AMGH in Tripoli during the year 2012. Data on potential risk factors were collected by a structured questionnaire and results of the test. The output data of questionnaire were used to assess potential risk factors for positive outcome. All sera (n = 500) was screened against ToxoG, by using the Vidas machine automated enzyme-linked florescent immunoassay. The association between the outcome variables and its potential risk factors were screened in a multivariate analysis. A p-value < 0.05 was considered to be significant. Results: The overall seroprevalence was estimated to be 50.8% with 95% confidence interval (CI) (46.42%–55.18%). The results revealed that T. gondii infection is highly prevalent, and eating habits (consuming raw meat and/or raw vegetables or fruits) were highly significant associated in multivariable analysis. Expectedly, a significantly [odds ratio (OR):1.712; p =
Abdusalam Sharef Abdusalam Mahmoud(1-2019)

Since 1998, southern Europe has experienced multiple incursions of different serotypes and topotypes of Bluetongue virus, a vector-borne transmitted virus, the causative agent of Bluetongue (BT), a major disease of ruminants. Some of these incursions originated from northern Africa, likely because of wind-blown dissemination of infected midges. In this report, we describe the detection and whole genome characterization of a novel BTV-3 strain identified in a symptomatic sheep in Tunisia. Sequences were immediately deposited with the GenBank Database under Accession Nos KY432369-KY432378. Alert and preparedness are requested to face the next vector seasons in northern Africa and the potential incursion of this novel strain in southern Europe arabic 11 English 57
Abdusalam Sharef Abdusalam Mahmoud(1-2021)

There were only 75 confirmed cases of coronavirus disease 2019 (COVID-19) reported in Libya by the National Center for Disease Control during the first two months following the first confirmed case on 24 March 2020. However, there was dramatic increase in positive cases from June to now; as of 19 November 2020, approximately 357940 samples have been tested by reverse transcription polymerase chain reaction, and the results have revealed a total number of 76808 confirmed cases, 47587 recovered cases and 1068 deaths. The case fatality ratio was estimated to be 1.40%, and the mortality rate was estimated to be 15.90 in 100000 people. The epidemiological situation markedly changed from mid-July to the beginning of August, and the country proceeded to the cluster phase. COVID19 has spread in almost all Libyan cities, and this reflects the high transmission rate of the virus at the regional level with the highest positivity rates, at an average of 14.54%. Apparently, there is an underestimation of the actual number of COVID-19 cases due to the low testing capacity. Consequently, the Libyan health authority needs to initiate a large-scale case-screening process and enforce testing capacities and contact testing within the time frame, which is not an easy task. Advisably, the Libyan health authority should improve the public health capacities and conduct strict hygienic measures among the societies and vaccinate as many people against COVID-19 to minimize both the case fatality ratio an
Abdusalam Sharef Abdusalam Mahmoud(1-2021)